18
validation: a new quantitative imaging biomarker for affected skin in scleroderma Giuseppina Abignano 1,2 Sibel Aydin 1 , Concepciòn Castillo-Gallego 1 , Daniel Woods 3 , Adam Meekings 3 , Dennis McGonagle 1 , Paul Emery 1 , Francesco Del Galdo 1 Optical Coherence Tomography 1. Scleroderma Programme, Leeds Institute of Molecular Medicine , UK 2. Rheumatology Unit, Second University of Naples, ITALY 3. Michelson, Diagnostics Ltd, Kent, UK

Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Embed Size (px)

Citation preview

Page 1: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

validation: a new quantitative imaging

biomarker for affected skin in

scleroderma

Giuseppina Abignano1,2

Sibel Aydin1, Concepciòn Castillo-Gallego1, Daniel Woods3, Adam Meekings3,

Dennis McGonagle1, Paul Emery1, Francesco Del Galdo1

Optical Coherence Tomography

1. Scleroderma Programme, Leeds Institute of Molecular Medicine , UK 2. Rheumatology Unit, Second University of Naples, ITALY 3. Michelson, Diagnostics Ltd, Kent, UK

Page 2: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Speaker: Dr Abignano Giuseppina

Title

“Optical coherence tomography validation:

a new quantitative imaging

biomarker for affected skin in scleroderma”

Has

• Nothing to Disclose

• No conflicts of interest

Page 3: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Systemic sclerosis (SSc):

multisystem disease with skin/internal organ involvement

Extent of skin involvement:

• major criterion to define limited and diffuse subsets

• survival and prognosis

• primary outcome in clinical trials

• still orphan of a quantitative imaging technique

LeRoy EC, J Rheumatol 1998

Steen VD, Arthritis Rheum 2001

Clements PJ, Arthritis Rheum 2000

Background/rationale

Page 4: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Modified Rodnan skin score (mRSS):

current gold standard used to measure skin thickness

• specific training and experience

• intra- and inter-observer variability of 12% and 25%

respectively

• may be not sensitive enough to measure small but clinically

meaningful changes in skin thickening

• sensitivity to change over time uncertain Merkel PA et al, J Rheumatol 2003

Clements PJ et al, J Rheumatol 2003

Clements PJ, Arthritis Rheum 1999

Background/rationale

Page 5: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Optical Coherence Tomography

“VivoSight” topical OCT probe (Michelson Diagnostics):

• laser wavelength: 1305 nm

• 100 OCT B-scans, inter-frame spacing of 4 µm

• 4 x 0.4 x 2 mm data volume (lateralx lateral x depth)

Page 6: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between
Page 7: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Previous studies have looked into structural details

of normal skin using

Optical Coherence Tomography (OCT)

but no studies have been previously published

with regard to the use of this technique in SSc

Mogensen M et al, Dermatology 2008

Welzel J et al, J Am Acad Dermatol 1997

Gambichler T et al, J Biomed Opt. 2005

Background/rationale

Page 8: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

concurrent validity when compared with skin biopsy construct validity when compared with clinical assessment (mRSS) intra- and inter-observer reliability for acquiring and reading images.

Aim

Page 9: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

37 subjects enrolled / 278 sites scanned (mRSS 0-3):

21 SSc patients: 11 D/ 10 L

mean (se) age: 53.8 (3.5) years

16 healthy (H) subjects: mean (se) age: 48 (4.8) years

Methods: subjects

Page 10: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

OCT dorsal aspect of forearm

C

B

A

ED

PD

RD

} {

} {

} {

} {

HEALTHY SSc

Page 11: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Comparison of OCT image/mean A-scans and skin biopsy

H

SSc

0

120

240

360

480

600

720

840

960

EDJ 60

0.0 0.2 0.4 0.6 0.8 1.0

hm

dep

th

Optical density

0

120

240

360

480

600

720

840

960

EDJ 60

0.0 0.2 0.4 0.6 0.8 1.0

hm

dep

th

Optical density

Page 12: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Mean A-Scan all groups

Page 13: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

P = 0.0031 P = 0.0295 P = 0.0451 P = ns P = 0.0272

Max OD (at 88-120 μm)

H vs mRSS 3 = 0.0031

H vs mRSS 2 = 0.0451

H vs mRSS 1 = 0.0295

H vs mRSS 0 = ns

Across 5 groups = 0.0272

Page 14: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Max gradient/Area

A

B

A. Maximum and mean

gradients of the mean A-scan

between the DE minimum

and the PD peak.

B. Area bounded by the PD

peak and the minimum value

of the DE valley.

Page 15: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Max gradient/Area inversely correlate with mRSS

mRSS=3

mRSS=2

mRSS=1

mRSS=0

Hea

lthy

0

200

400

600

Ma

x g

rad

ien

t

**

*

*

*

mRSS=3

mRSS=2

mRSS=1

mRSS=0

Hea

lthy

0

10000

20000

30000

40000

50000

60000

Pa

pD

Bu

lge

A

**

* *

*

Page 16: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Intra-observer reliability (10 sites, 1 operator, different scanning session): A. ICC = 0.91, LoA = 0.63 - 0.97 B. ICC = 0.95, LoA = 0.79 - 0.99 Inter-observer reliability (10 sites, 2 operators, same scanning session): A. ICC = 0.89, LoA= 0.61-0.97 B. ICC = 0.91, LoA = 0.66-0.97

Results: reliability

B

A

Page 17: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

We have demonstrated that OCT is:

able to measure the increase in ECM in the basal

membrane and papillary dermis affording a pathological

explanation for the OCT findings.

able to discriminate between different grades of skin

involvement

a reproducible technique

OCT appears to be a promising new imaging tool in SSc

Conclusions

Page 18: Optical Coherence Tomography validation: a new ... · validation: a new quantitative imaging ... a new quantitative imaging biomarker for affected skin in scleroderma ... between

Aknowledgements

Dr. Francesco Del Galdo Prof. Paul Emery Prof. Dennis McGonagle Dr. Richard Wakefield Dr. Maya Buch Dr. Sibel Aydin Dr. Concepciòn Castillo-Gallego

University of Leeds

Daniel Woods Adam Meekings

Michelson Diagnostics Ltd.